| |
Hospira Receives FDA Approval for Azithromycin for Injection
Mon Jun 29 (PR Newswire)
Hospira, Inc. , the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration approval for a 500 mg vial of azithromycin for injection in the ADD-VantageŽ System.
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 14B | | Price
/ Earnings: | 12.2 | | Price
/ Book: | 11.3 | | Net
Profit Margin (mrq): | 15.3% | | Price
To Free Cash Flow (mrq): | -33.0 | | Return
on Equity: | 23.8% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.4% |
|